PPARG and diabetes mellitus: A recent meta-analysis has also been performed to examine the cardiovasculareffects of the PPARγ agonist, rosiglitazone, which includes outcome data from 35trials, such as the large Diabetes Reduction Assessment with Ramipiril and Rosiglitazone Medication (DREAM) trial and the A DiabetesOutcome Prevention Trial (ADOPT) [99–101].This meta-analysis demonstrated that treatment with rosiglitazone increased therisk for MI by 43% (P = .03), and deathfrom cardiovascular causes by 64% (P = .06).